Conflicting Views on Embryonic and Adult Stem Cells Complicate Research in Stem Cell Therapeutics.

Business Editors/Health/Medical Writers

PALO ALTO, Calif.--(BUSINESS WIRE)--June 15, 2004

Though there has been considerable biological and political debate over the use of embryonic stem cells (ESCs) vs. adult stem cells (ASCs) as therapies for tissue engineering and organ transplants, inherent benefits and drawbacks in both techniques compel them to coexist and complement each other.

"On the one hand, it's been very difficult to grow sufficient numbers of ASCs to regenerate tissues or create replacement organs," explains Technical Insights Research Analyst Katherine Austin. "On the other hand, ESCs provoke immune rejection much like any other transplant, and it's also been difficult to grow them in culture without mouse or other animal cells. These obstacles should be overcome in the near future, however."

It is possible to use a procedure called nuclear transplantation to replace the DNA of an embryonic stem cell with DNA from one of the patient's own cells, eliminating the problem of immune rejection. In another approach, differentiating small numbers of ESCs into blood cells and injecting them into the patient creates immune tolerance for other cells types derived from the ESCs, thereby reducing the intensity of rejection by the body.

ASCs, on the other hand, are patient derived and do not face the problem of immune rejection. However, for the most part they have not been as versatile as ESCs, exhibiting only those properties specific to their point of origin. For example, brain and hematopoietic stem cells give rise only to neural tissue and blood cells, respectively.

ASCs' presence in several mature tissues, including bone marrow, blood, adipose tissue, and the brain offsets their inability to differentiate into numerous types of tissues. Recent research has also detected rare ASCs that are 'pluripotent' and hence, capable of forming numerous cell types of the body.

Secondly, ASCs may be unsuitable for regeneration of damaged tissues in the case of elderly patients or due to presence of cancer in the bone marrow. In addition, ASCs are restricted to the individual patient, making it difficult to spread the cost of isolation and expansion among multiple recipients. Some groups have found, however, that certain ASCs do not cause immune rejection, allowing cells to be pooled from many patients, which would solve this problem.

Though biological hurdles are common ground for both ASCs and ESCs, the latter face political barriers because they originate from discarded human embryos or aborted fetuses stored at in vitro fertilization clinics. Another method that has raised political hackles is 'therapeutic cloning,' which involves the creation of a cloned embryo using the patient's DNA.

Fueling such controversies are stringent regulatory practices specifically in the United States such as President Bush's decree in August 2001 forbidding federal funding for research on ESCs, with the exception of those derived from the approved twelve existing stem cell lines.

Following the Bush decree, of the $370 million in grants awarded by the National Institute of Health (NIH) during 2002 for animal and human stem cells, only $10 million went to research involving human ESCs. The ESCs are also expensive at $5,000 per vial, forcing NIH to subsidize cell culturing or offer supplements to its grants in order to cover the extra cost.

Quality control is another critical issue in stem cell therapies, where assessing products containing combinations of active substances and live cells become extremely complex. Addressing this issue during the early stages of design will avoid future delays in product approval and post-approval recalls.

"Contamination is a constant threat, hence living cells grown in vitro for organ transplants and regenerating damaged tissues must be cultured under GMP (good manufacturing practice) conditions in order to meet the FDA quality standards," concludes Austin.

Emerging Technologies in Stem Cell Therapeutics analysis is part of the Healthcare Vertical Subscription Service, and provides a comprehensive analysis of the technologies used in developing stem cell therapies along with upcoming stem cell treatments for various ailments. It analyzes key technical challenges and drivers influencing growth and provides in-depth examination of cutting-edge developments. Executive summaries and interviews are available to the press.

If you are interested in an analysis overview which provide manufacturers, end-users and other industry participants an overview, summary, challenges and latest coverage of Emerging Technologies in Stem Cell Therapeutics -- then send an email to Julia Paulson -- North American Corporate Communications at [e-mail] with the following information: Full name, Company Name, Title, Contact Tel Number, Contact Fax Number, Email. Upon receipt of the above information, an overview will be emailed to you.

Technical Insights is an international technology analysis business that produces a variety of technical news alerts, newsletters, and research services.

Frost & Sullivan, an international growth consultancy, has been supporting clients' expansion for more than four decades. Our market expertise covers a broad spectrum of industries, while our portfolio of advisory competencies includes custom strategic consulting, market intelligence, and management training. Our mission is to forge partnerships with our clients' management teams to deliver market insights and to create value and drive growth through innovative approaches. Frost & Sullivan's network of consultants, industry experts, corporate trainers, and support staff spans the globe with offices in every major country.

Emerging Technologies in Stem Cell Therapeutics

D284

Keywords in this release: stem cells, embryonic stem cells, ESCs, adult stem cells, ASCs, tissue engineering, organ transplants, pluripotent, hematopoietic stem cells, therapeutic cloning, National Institute of Health, NIH